EGFR and non-small cell lung carcinoma: AICAR, a purine biosynthesis intermediate, inhibits EGFR-mutant NSCLC by inducing DNA damage and apoptosis, with potential crosstalk with ferroptosis through AMPK activation and subsequent modulation of lipid metabolism (84).